These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 31752169)

  • 21. Current Development of Glioblastoma Therapeutic Agents.
    Wang Z; Peet NP; Zhang P; Jiang Y; Rong L
    Mol Cancer Ther; 2021 Sep; 20(9):1521-1532. PubMed ID: 34172531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.
    Bastien JI; McNeill KA; Fine HA
    Cancer; 2015 Feb; 121(4):502-16. PubMed ID: 25250735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age.
    Gray GK; McFarland BC; Nozell SE; Benveniste EN
    Expert Rev Neurother; 2014 Nov; 14(11):1293-306. PubMed ID: 25262780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
    Reddy RG; Bhat UA; Chakravarty S; Kumar A
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A New Chalcone Derivative with Promising Antiproliferative and Anti-Invasion Activities in Glioblastoma Cells.
    Mendanha D; Vieira de Castro J; Moreira J; Costa BM; Cidade H; Pinto M; Ferreira H; Neves NM
    Molecules; 2021 Jun; 26(11):. PubMed ID: 34205043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.
    Graner MW; Bigner DD
    Expert Rev Anticancer Ther; 2006 May; 6(5):679-95. PubMed ID: 16759160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel CXCR4 Inhibitor CPZ1344 Inhibits the Proliferation, Migration and Angiogenesis of Glioblastoma.
    Luo Z; Wang B; Chen Y; Liu H; Shi L
    Pathol Oncol Res; 2020 Oct; 26(4):2597-2604. PubMed ID: 32632898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contribution of the Wnt Pathway to Defining Biology of Glioblastoma.
    Tompa M; Kalovits F; Nagy A; Kalman B
    Neuromolecular Med; 2018 Dec; 20(4):437-451. PubMed ID: 30259273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances in heat shock proteins in cancer diagnosis, prognosis, metabolism and treatment.
    Yang S; Xiao H; Cao L
    Biomed Pharmacother; 2021 Oct; 142():112074. PubMed ID: 34426258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dissecting the functional significance of HSP90AB1 and other heat shock proteins in countering glioblastomas and ependymomas using omics analysis and drug prediction using virtual screening.
    Sharma S; Kumar P
    Neuropeptides; 2023 Dec; 102():102383. PubMed ID: 37729687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
    Mao H; Lebrun DG; Yang J; Zhu VF; Li M
    Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcription factors in glioblastoma - Molecular pathogenesis and clinical implications.
    Papavassiliou KA; Papavassiliou AG
    Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188667. PubMed ID: 34894431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A New Investigational Perspective for Purines Against Glioblastoma Invasiveness.
    Giuliani P; Zuccarini M; Carluccio M; Ziberi S; Di Iorio P; Caciagli F; Ciccarelli R
    Curr Drug Targets; 2018; 19(16):1871-1881. PubMed ID: 29484991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The heat shock response and chaperones/heat shock proteins in brain tumors: surface expression, release, and possible immune consequences.
    Graner MW; Cumming RI; Bigner DD
    J Neurosci; 2007 Oct; 27(42):11214-27. PubMed ID: 17942716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular signaling molecules as therapeutic targets in glioblastoma multiforme.
    Jagannathan J; Prevedello DM; Dumont AS; Laws ER
    Neurosurg Focus; 2006 Apr; 20(4):E8. PubMed ID: 16709039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eph receptors as therapeutic targets in glioblastoma.
    Day BW; Stringer BW; Boyd AW
    Br J Cancer; 2014 Sep; 111(7):1255-61. PubMed ID: 25144626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting glioblastoma stem cells: cell surface markers.
    He J; Liu Y; Lubman DM
    Curr Med Chem; 2012; 19(35):6050-5. PubMed ID: 22963566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth.
    Lee J; Shin YJ; Lee K; Cho HJ; Sa JK; Lee SY; Kim SH; Lee J; Yoon Y; Nam DH
    Cancer Res Treat; 2018 Jul; 50(3):1009-1022. PubMed ID: 29129044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surfaceome Proteomic of Glioblastoma Revealed Potential Targets for Immunotherapy.
    Rose M; Cardon T; Aboulouard S; Hajjaji N; Kobeissy F; Duhamel M; Fournier I; Salzet M
    Front Immunol; 2021; 12():746168. PubMed ID: 34646273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
    Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
    Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.